August 7, 2025 Nordic Group B.V. Through its Subsidiary Nordic Pharma, Inc. (U.S.), Announces LACRIFILL® Canalicular Gel Inclusion in New Dry Eye Workshop (DEWS) III Management and Therapy Report From The Tear Film and Ocular Surface Society (TFOS) in American Journal...
February 28, 2025 Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announced today a poster presentation at SECO 2025 being held from February 26 – March 2 in Atlanta, Georgia. Mile Brujic, OD, FAAO of Premier Vision Group will present this poster on Novel...
October 17, 2024 Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. in April and will continue its introduction to leading ophthalmologists during AAO 2024. LACRIFILL Canalicular Gel is a...
March 4, 2024 Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V.,...
February 26, 2024 Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today that preeminent ophthalmologist Eric D. Donnenfeld, MD will Chair its U.S. Medical Advisory Board (MAB) which includes Richard Lindstrom, MD...
Recent Comments